Stock Financial Ratios, Dividends, Split History

ANTH / Anthera Pharmaceuticals, Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Market Cap ($M)3.06
Enterprise Value ($M)-5.02
Book Value ($M)5.46
Book Value / Share0.21
Price / Book0.56
NCAV ($M)5.39
NCAV / Share0.21
Price / NCAV0.57
Share Statistics
Common Stock Shares Outstanding 13,854,491
Common Shares Outstanding 23,520,714
Weighted Average Number Of Shares Outstanding Basic 10,278,391
Scoring Models
Piotroski F-Score3.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)4.89
Return on Assets (ROA)-1.14
Return on Equity (ROE)-2.16
Balance Sheet (mrq) ($M)
Quick Ration/a
Current Ratio3.30
Income Statement (mra) ($M)
Revenue From Related Parties0.00
Revenue From Grants0.00
Licenses Revenue0.00
Operating Income-36.43
Net Income-26.87
Earnings Per Share Basic And Diluted-2.86
Cash Flow Statement (mra) ($M)
Cash From Operations-36.90
Identifiers and Descriptors
Central Index Key (CIK)1316175
Related CUSIPS
03674U901 03674U951 03674U102 03674U300

Split History

Stock splits are used by Anthera Pharmaceuticals, Inc. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon
ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

Related News Stories

BRIEF-Anthera Pharma's Board Approves Personnel Reorganization Plan

2018-04-16 reuters

Anthera Fails Phase 3 Study, Time To Avoid

2018-03-15 seekingalpha
Anthera fails Phase 3 study using sollpura treating patients with exocrine pancreatic insufficiency due to cystic fibrosis. (18-7)

Complement Targeted Medicine, IgA Nephropathy, And Why You Should Pay Attention To Omeros

2018-03-15 seekingalpha
Complement immunity is a complicated landscape of regulatory proteins and effectors that can initiate and/or amplify an immune response. (18-1)

U.S. Biotech/Pharma Sector Daily Observations Letter: March 13, 2018

2018-03-14 seekingalpha
Anthera Pharmaceuticals (ANTH) is trading at a market cap of just $11.3 million (with cash reserves of $16M and net operating loss carryforwards of $7.5M). (85-1)

CUSIP: 03674U201